Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPROACH: Ad26 Mosaic and gp140 HIV Vaccine
NCT02315703Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2014
- Primary completion
- Aug 2017
- Modality
- Prophylactic Vaccines, Viral Vectors, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of Ad26.Mos4.HIV, MVA-Mosaic and HIV-1 Clade C gp140 protein in human immunodeficiency virus infection (HIV) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants With Solicited Local Adverse Events, Percentage of Participants With Solicited Systemic Adverse Events and 3 more. Started Dec 2014; status: completed.
02
Drugs
Ad26.Mos4.HIVMVA-MosaicHIV-1 Clade C gp140 protein
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02315703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315703.